BioCardia (NASDAQ:BCDA) & Spyre Therapeutics (NASDAQ:SYRE) Head-To-Head Review

Spyre Therapeutics (NASDAQ:SYRE) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Spyre Therapeutics and BioCardia”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$208.02 million	($2.19)	-10.28
BioCardia	N/A	N/A	-$7.95 million	($1.85)	-0.70

Spyre Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Spyre Therapeutics has a beta of 2.99, indicating that its stock price is 199% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Spyre Therapeutics and BioCardia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-71.30%	-38.69%
BioCardia	N/A	-19,117.42%	-246.92%

Institutional & Insider Ownership

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 15.4% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Spyre Therapeutics and BioCardia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1	0	6	2	3.00
BioCardia	1	1	1	1	2.50

Spyre Therapeutics currently has a consensus target price of $52.50, indicating a potential upside of 133.13%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 1,823.08%. Given BioCardia’s higher possible upside, analysts plainly believe BioCardia is more favorable than Spyre Therapeutics.

Summary

Spyre Therapeutics beats BioCardia on 7 of the 12 factors compared between the two stocks.

About Spyre Therapeutics

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.